One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks discontinuation of treatment

被引：0

作者：

Bunck, M. C. ^{[1
]}

Mari, A. ^{[2
]}

Corner, A. ^{[3
]}

Eliasson, B. ^{[4
]}

Shaginian, R. M. ^{[5
]}

Wu, Y. ^{[6
]}

Yan, P. ^{[6
]}

Heine, R. J. ^{[1
,7
]}

Smith, U. ^{[4
]}

Taskinen, M. -R. ^{[3
]}

Yki-Jarvinen, H. ^{[3
]}

Diamant, M. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, Ctr Diabet, Amsterdam, Netherlands

[2] Inst Biomed Engn, Padua, Italy

[3] Univ Helsinki, Cent Hosp, Dept Med, FIN-00014 Helsinki, Finland

[4] Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden

[5] Eli Lilly & Co, Houten, Netherlands

[6] Amylin Pharmaceut Inc, San Diego, CA USA

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

DIABETOLOGIA | 2009年 / 52卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S7 / S7

页数：1

共 50 条

[1] One year treatment with exenatide improves β cell function and glycaemic control in metformin treated type 2 diabetes patients
Bunck, M. C.
Diamant, M.
Corner, A.
Eliasson, B.
Malloy, J. L.
Shaginian, R. M.
Deng, W.
Kendall, D. M.
Taskinen, M.-R.
Smith, U.
Yki-Jarvinen, H.
Heine, R. J.
DIABETOLOGIA, 2007, 50 : S111 - S112
[2] One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial
Bunck, Mathijs C.
Diamant, Michaela
Corner, Anja
Eliasson, Bjorn
Malloy, Jaret L.
Shaginian, Rimma M.
Deng, Wei
Kendall, David M.
Taskinen, Marja-Riitta
Smith, Ulf
Yki-Jarvinen, Hannele
Heine, Robert J.
DIABETES CARE, 2009, 32 (05) : 762 - 768
[3] Exenatide: One year of treatment improves beta-cell function in type 2 diabetics
Sauvanet, J. -P.
ANNALES D ENDOCRINOLOGIE, 2007, 68 (06)
[4] One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice
Buysschaert, M.
Preumont, V.
Oriot, P. R.
Paris, I.
Ponchon, M.
Scarniere, D.
Selvais, P.
DIABETES & METABOLISM, 2010, 36 (05) : 381 - 388
[5] Exenatide : one year of treatment improves the beta-cellular fuction in type 2 diabetics
Sauvanet, J. -P.
DIABETES & METABOLISM, 2007, 33 (05)
[6] Exenatide improves postprandial hyperglycemia and dyslipidemia in metformin treated patients with type 2 diabetes
Bunck, Mathijs C.
Corner, Anja
Diamant, Michaela
Eliasson, Bjorn
Malloy, Jaret L.
Shaginian, Rimma M.
Ding, Wei
Kendall, David M.
Smith, Ulf
Yki-Jarvinen, Hannele
Heine, Robert J.
Taskinen, Marja-Ritta
DIABETES, 2008, 57 : A33 - A33
[7] Exenatide improves postprandial hyperglycaemia and dyslipidaemia in metformin treated patients with type 2 diabetes
Bunck, M. C.
Corner, A.
Diamant, M.
Eliasson, B.
Malloy, J. L.
Shaginian, R. M.
Deng, W.
Kendall, D. M.
Smith, U.
Yki-Jarvinen, H.
Heine, R. J.
Taskinen, M. R.
DIABETOLOGIA, 2008, 51 : S351 - S351
[8] Endobarrier treatment for longstanding type 2 diabetes and obesity: Outcomes one-year after endobarrier in 90 consecutively treated patients
Ryder, R. E. J.
Sen Gupta, P.
Burbridge, W.
Irwin, S. P.
Bashir, T.
Allden, R. A.
Bleasdale, J. P.
Fogden, E. N.
Anderson, M. R.
Yadagiri, M.
DIABETIC MEDICINE, 2021, 38
[9] Effects of one-year treatment with canagliflozin or sitagliptin on glycaemic control and beta cell function measures in subjects with type 2 diabetes on metformin plus sulfonylurea
Schernthaner, G.
Ferrannini, E.
Mari, A.
Tong, C.
Kawaguchi, M.
Meininger, G.
Polidori, D.
DIABETOLOGIA, 2013, 56 : S398 - S399
[10] Extended, 3-year, exenatide therapy shows sustainable effects on beta cell disposition index in metformin treated patients with type 2 diabetes
Bunck, M. C.
Corner, A.
Eliasson, B.
Heine, R. J.
Shaginian, R. M.
Taskinen, M. -R.
Smith, U.
Yki-Jarvinen, H.
Diamant, M.
DIABETOLOGIA, 2010, 53

← 1 2 3 4 5 →